Vaginal leiomyoma

Summary

Vaginal leiomyoma (MONDO:0001536) is a disease. A subtype of benign vaginal neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vaginal leiomyoma
Mondo ID	MONDO:0001536
DOID	DOID:125
NCIT	C6373
UMLS	C1336939
MedGen	277859
Anatomy (UBERON)	UBERON:0000996
Is cancer (heuristic)	no

Also known as: leiomyoma of the vagina · leiomyoma of vagina · vagina leiomyoma · vaginal leiomyoma

Disease family

This is a subtype of benign vaginal neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › benign reproductive system neoplasm › benign female reproductive system neoplasm › benign vaginal neoplasm › vaginal leiomyoma

Related subtypes (3): vaginal mullerian papilloma, benign vaginal mixed epithelial and mesenchymal neoplasm, vaginal squamous papilloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.